KR100281265B1 - 신규한 스핀고당지질 및 그의 사용 - Google Patents

신규한 스핀고당지질 및 그의 사용 Download PDF

Info

Publication number
KR100281265B1
KR100281265B1 KR1019950704460A KR19950704460A KR100281265B1 KR 100281265 B1 KR100281265 B1 KR 100281265B1 KR 1019950704460 A KR1019950704460 A KR 1019950704460A KR 19950704460 A KR19950704460 A KR 19950704460A KR 100281265 B1 KR100281265 B1 KR 100281265B1
Authority
KR
South Korea
Prior art keywords
compound
amino
lactopyranosyl
glucopyranosyl
octadecanetriol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019950704460A
Other languages
English (en)
Korean (ko)
Inventor
다추오 히가
다케노리 나토리
야스히코 고에주카
가즈히로 모토키
Original Assignee
마나배 게이사꾸
기린비이루 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마나배 게이사꾸, 기린비이루 가부시키가이샤 filed Critical 마나배 게이사꾸
Application granted granted Critical
Publication of KR100281265B1 publication Critical patent/KR100281265B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1019950704460A 1993-04-15 1994-04-14 신규한 스핀고당지질 및 그의 사용 Expired - Fee Related KR100281265B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP88630/1993 1993-04-15
JP8863093 1993-04-15
PCT/JP1994/000625 WO1994024142A1 (fr) 1993-04-15 1994-04-14 Nouveau sphingoglycolipide et son utilisation

Publications (1)

Publication Number Publication Date
KR100281265B1 true KR100281265B1 (ko) 2001-02-01

Family

ID=13948136

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704460A Expired - Fee Related KR100281265B1 (ko) 1993-04-15 1994-04-14 신규한 스핀고당지질 및 그의 사용

Country Status (11)

Country Link
US (1) US5780441A (enExample)
EP (1) EP0694558B1 (enExample)
JP (1) JP4020958B2 (enExample)
KR (1) KR100281265B1 (enExample)
CN (1) CN1045302C (enExample)
AT (1) ATE176237T1 (enExample)
AU (1) AU683653B2 (enExample)
CA (1) CA2160566C (enExample)
DE (1) DE69416306T2 (enExample)
TW (1) TW295588B (enExample)
WO (1) WO1994024142A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW261533B (enExample) * 1992-07-16 1995-11-01 Kirin Brewery
TW555562B (en) * 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
WO1998034623A1 (en) * 1997-02-05 1998-08-13 Kirin Beer Kabushiki Kaisha Freeze-dried composition containing glycosphingolipid and process for producing the same
ES2235324T3 (es) 1997-04-10 2005-07-01 Kirin Beer Kabushiki Kaisha Empleo de a-glicosilceramidas para la obtencion de un agente terapeutico para enfermedades autoinmunes.
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
AU765809B2 (en) * 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
JPH11269189A (ja) * 1998-03-19 1999-10-05 Nissin Food Prod Co Ltd 免疫調節作用を有する化合物
JP4099267B2 (ja) * 1998-08-07 2008-06-11 株式会社紀文フードケミファ 乳化剤および乳化組成物
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
CA2453880A1 (en) * 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CA2493690C (en) * 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20050222048A1 (en) * 2004-03-31 2005-10-06 The Research Foundation Of The City University Of New York Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
US8022043B2 (en) * 2004-08-27 2011-09-20 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
AU2005280163B2 (en) 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
KR101243577B1 (ko) 2004-10-07 2013-03-20 아고스 쎄라퓨틱스, 인코포레이티드 성숙 수지상 세포 조성물 및 그의 배양 방법
US9295722B2 (en) 2005-01-28 2016-03-29 The Scripps Research Institute Bacterial glycolipid activation of CD1d-restricted NKT cells
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
EP1776963A1 (en) 2005-10-19 2007-04-25 Gbf-Gesellschaft Für Biotechnologische Forschung Mbh Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
US20070231344A1 (en) * 2005-10-28 2007-10-04 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
SI2056842T1 (sl) 2006-04-07 2013-02-28 The Scripps Research Institute Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
JP5564672B2 (ja) * 2006-06-30 2014-07-30 ザ スクリプス リサーチ インスティテュート アジュバント及びその使用方法
EP2112930B1 (en) 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cdid molecules
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2058011A1 (en) * 2007-11-07 2009-05-13 Wittycell Nkt cell activating gycolipids covalently bound antigens and/or drug
EP2060252A1 (en) 2007-11-19 2009-05-20 Wittycell New formulation of galactosylceramide derivatives
AU2008350531B2 (en) * 2007-12-05 2014-01-23 Abivax Use of glycosylceramides for enhancing the immune response to antigens
CN102215864A (zh) * 2008-10-08 2011-10-12 威蒂赛尔公司 用于抗流感的疫苗组合物
KR20110137290A (ko) * 2009-01-08 2011-12-22 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
WO2010083728A1 (en) 2009-01-23 2010-07-29 Dapeng Zhou Nanoparticle formulated glycolipid antigens for immunotherapy
ES2675582T3 (es) 2010-12-02 2018-07-11 Riken Inmunoterapia utilizando células alo-NKT, células para inmunoterapia en las que la cadena alfa del gen del receptor de las células T (TCR) ha sido redistribuida a V alfa-J alfa uniforme, y banco de células NKT derivadas de dichas células
EP2889039B1 (en) 2012-08-22 2017-11-08 Regimmune Corporation Preparation for preventing or treating type i diabetes
WO2014069655A1 (ja) 2012-11-05 2014-05-08 株式会社レグイミューン 免疫寛容誘導剤
AU2013349706B2 (en) 2012-11-21 2019-08-22 Assistance Publique - Hopitaux De Paris Methods for determining the risk of acute graft versus host disease
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
CN106726875B (zh) * 2016-11-24 2019-05-21 晨光生物科技集团股份有限公司 一种含鞘糖脂类物质的提取物的制备方法
IL303285A (en) 2020-12-04 2023-07-01 Regimmune Corp Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4598051A (en) * 1980-03-12 1986-07-01 The Regents Of The University Of California Liposome conjugates and diagnostic methods therewith
US4806466A (en) * 1981-10-29 1989-02-21 The Regents Of The University Of California Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
JPS6157594A (ja) * 1984-08-30 1986-03-24 Suntory Ltd ガラクトスフインゴ脂質及びその製造法
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
ZA866023B (en) * 1985-08-13 1987-03-25 Solco Basel Ag New process for the preparation of sphingosine derivatives
JPH07116209B2 (ja) * 1986-04-11 1995-12-13 メクト株式会社 シアロシルセラミド類及びその製造方法
US4990603A (en) * 1986-07-04 1991-02-05 Mect Corporation Sialic acid derivatives and process therefor
US4937232A (en) * 1986-09-15 1990-06-26 Duke University Inhibition of protein kinase C by long-chain bases
US4816450A (en) * 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
JPS6495A (en) * 1986-12-19 1989-01-05 Tosoh Corp Alpha-glycosyl ceramide derivative
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JP2588729B2 (ja) * 1987-10-05 1997-03-12 塩野義製薬株式会社 スフィンゴシン誘導体
US5041441A (en) * 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3840044A1 (de) * 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
US5028715A (en) * 1989-02-06 1991-07-02 Southwest Research Institute Radioprotective agents and their method of manufacture
DE69011465T2 (de) * 1989-09-29 1995-03-23 Ajinomoto Kk Verwendung von Human-ADF (=Adult T-cell leukemia-derived factor) zur Herstellung von Medikamenten.
JP3068910B2 (ja) * 1990-11-08 2000-07-24 麒麟麦酒株式会社 新規スフィンゴ糖脂質、その製造法および使用
JPH06145189A (ja) * 1991-01-23 1994-05-24 Kitasato Inst:The スフィンゴ糖脂質
JPH0559081A (ja) * 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
TW261533B (enExample) * 1992-07-16 1995-11-01 Kirin Brewery
US5567684A (en) * 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives

Also Published As

Publication number Publication date
CN1045302C (zh) 1999-09-29
CA2160566A1 (en) 1994-10-27
CA2160566C (en) 2004-07-13
JP4020958B2 (ja) 2007-12-12
CN1124963A (zh) 1996-06-19
AU6513094A (en) 1994-11-08
AU683653B2 (en) 1997-11-20
EP0694558B1 (en) 1999-01-27
EP0694558A1 (en) 1996-01-31
TW295588B (enExample) 1997-01-11
ATE176237T1 (de) 1999-02-15
EP0694558A4 (en) 1996-08-21
US5780441A (en) 1998-07-14
WO1994024142A1 (fr) 1994-10-27
DE69416306T2 (de) 1999-06-17
DE69416306D1 (de) 1999-03-11

Similar Documents

Publication Publication Date Title
KR100281265B1 (ko) 신규한 스핀고당지질 및 그의 사용
JPWO1994024142A1 (ja) 新規スフィンゴ糖脂質およびその使用
JP3088461B2 (ja) 新規医薬組成物
JP3717512B2 (ja) 新規スフィンゴ糖脂質およびその使用
US6503885B1 (en) Carboxymethylgalactose derivatives
KR100527950B1 (ko) 알파-글리코실세라미드를 함유하는 엔케이티 세포활성화제
JP2774194B2 (ja) 新規スフィンゴ糖脂質およびその使用
US5936076A (en) αgalactosylceramide derivatives
RU2170738C2 (ru) Замещенные липосахариды, используемые для лечения и профилактики эндотоксикоза
EP2842961B1 (en) New carbamate glycolipid and use thereof
JPWO1994009020A1 (ja) 新規スフィンゴ糖脂質およびその使用
KR19980703591A (ko) 당 개질된 세포 증식 억제제
KR20050062551A (ko) α-글리코실세라미드를 유효 성분으로 하는 Ｃ형 간염 바이러스 억제제
WO2011096536A1 (ja) 新規合成糖脂質およびその用途
EP2514759A1 (en) Triterpene derivative, and prophylactic or therapeutic agent for chronic hepatitis c
KR0142228B1 (ko) 신규 안트라사이클린 글리코시드유도체 및 그 제조방법
HK1207648B (en) New carbamate glycolipid and use thereof
HK1009937B (en) Novel medicinal composition
HK1009968B (en) Novel sphingoglycolipid and use thereof
HK1158549A1 (en) Treatment of cancers of the blood using selected glycomimetic compounds
HK1009967B (en) Novel sphingoglycolipid and use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20081015

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20091117

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20091117

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000